|1.||Urade, Yoshihiro: 4 articles (10/2008 - 12/2002)|
|2.||Inoue, Tsuyoshi: 3 articles (10/2007 - 12/2002)|
|3.||Matsumura, Hiroyoshi: 3 articles (10/2007 - 12/2002)|
|4.||Cummins, Robert: 2 articles (05/2014 - 01/2011)|
|5.||Pidgeon, Graham P: 2 articles (05/2014 - 01/2011)|
|6.||O'Byrne, Kenneth J: 2 articles (05/2014 - 01/2011)|
|7.||Gately, Kathy: 2 articles (05/2014 - 01/2011)|
|8.||Werz, Oliver: 2 articles (03/2011 - 08/2009)|
|9.||FitzGerald, Garret A: 2 articles (08/2010 - 07/2010)|
|10.||Wang, Miao: 2 articles (08/2010 - 07/2010)|
02/01/1998 - "Elevated platelet TXA2/PGH2 receptor levels and enhanced sensitivity of platelet aggregation to TXA2 predict early arterial graft thrombosis. "
02/01/1998 - "Preoperative platelet TXA2/PGH2 receptor density was higher (Bmax, 3100 +/- 1300 vs 1500 +/- 1100 sites/platelet [mean +/- SD]; p = 0.004) in the five patients who had graft thrombosis within 3 months. "
04/01/1984 - "Because 13-APA does not interfere with arachidonic acid metabolism, the ability of 13-APA to suppress thrombus formation is presumably due to direct antagonism of TXA2/PGH2 at the platelet receptor level. "
02/01/1998 - "Early graft thrombosis was more likely in patients with a platelet TXA2/PGH2 receptor density greater than 3000 sites/platelet (odds ratio, 76; 95% confidence interval, 3.9 to 1500) or an EC50 for U46619 less than 30 nmol/L (odds ratio, 16; 95% confidence interval, 1.4 to 180). "
05/01/1985 - "The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of the therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists. "
|2.||Hypertension (High Blood Pressure)
10/01/1996 - "Therefore, the aim of these studies was to compare the antihypertensive efficacy of an ANG II type I (AT1) and a TxA2/PGH2 receptor antagonist during different phases of 2K,1C hypertension. "
11/01/2000 - "Collectively, these findings suggest that in hypertension, endothelium-derived ET and PGH(2)/TxA(2) increase the Ca(2+) sensitivity of the contractile apparatus of arteriolar smooth muscle; thus, the similar increases in [Ca(2+)](i) in response to the elevation of intraluminal pressure elicit greater myogenic constriction."
12/01/1997 - "Infusion of the TxA2/PGH2 mimetic, U-46,619, into conscious rats leads to hypertension that is potentiated by a high-salt intake. "
08/01/1997 - "Sympathetic nervous system and hypertension during prolonged TxA2/PGH2 receptor activation in rats."
10/12/2001 - "However, PGHS-dependent vasoconstriction (mediated by thromboxane and/or its immediate precursor, PGH(2)) predominates in some vascular pathologies (eg, systemic hypertension, diabetes, cerebral ischemia, and aging). "
|4.||Coronary Stenosis (Coronary Artery Stenosis)
03/01/1989 - "The object of this study was to test the hypothesis that administration of both serotonin S2 and thromboxane A2-prostaglandin H2 (PGH2) receptor antagonists provides significant protection against epinephrine-induced cyclic coronary artery flow variations in open chest, anesthetized dogs with severe proximal coronary artery stenosis and endothelial injury. "
05/01/1994 - "These findings suggest that PGH2 does not contribute to impaired endothelium-dependent relaxation and that long-term administration of L-NAME promotes atherosclerosis by inhibition of NO synthesis in the hypercholesterolemic rabbit thoracic aorta."
03/01/2002 - "TXA2/PGH2 receptor inhibitors may contribute to the reduction in formation of atherosclerosis in lesions with vascular injury by enhancing the production of nitric oxide by VSMCs."
10/01/2008 - "Recent studies suggest that lipocalin-type prostaglandin (PG) D synthase (L-PGDS), which converts PGH2 to PGD2, is implicated in the pathogenesis of atherosclerosis. "
11/01/2010 - "TxA2, F2-isoprostanes, prostaglandins endoperoxides PGG2/PGH2) are known to promote the initiation and progression of atherosclerosis, not only via platelet activation, but through leukocyte-endothelial interactions and vasoconstriction. "
08/01/1988 - "Atherosclerosis was induced in New Zealand White rabbits by feeding them a 0.5% cholesterol-enriched rabbit chow for 10-12 wk. Half of the cholesterol-fed rabbits were given BM 13505, a specific thromboxane A2/endoperoxide (TxA2/PGH2) receptor antagonist, and the other half were given its vehicle (i.e., 2% Na2CO3). "
|1.||Prostaglandin H2 (PGH(2))
|2.||Thromboxane A2 (A2, Thromboxane)
|3.||Aspirin (Acetylsalicylic Acid)
|4.||Serotonin (5 Hydroxytryptamine)
|6.||Tissue Plasminogen Activator (Alteplase)
|9.||Arachidonic Acid (Vitamin F)
|10.||Prostaglandins E (PGE)
|2.||Transplantation (Transplant Recipients)